Alimentary pharmacology & therapeutics
Cure8 research brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, Risankizumab, and IL-23 inhibitor. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAlimentary pharmacology & therapeutics
AuthorsErnest-Suárez K, Hoentjen F
Study typeEditorial
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 13, 2026, 12:00 AM
Content availableMetadata only
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
Physician Views Preview: J&J's Tremfya approved in Crohn's disease — can it compete?
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.
FDA Grants New Indication for Omvoh for Moderate to Severe Crohn's Disease
Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Mirikizumab. The original article is from specialtypharmacycontinuum.com.
FDA okays J&J's Tremfya for Crohn's, offering IV and subcutaneous induction options
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.